A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab

Yamamoto, 2022, Epidemiologic study on gestational trophoblastic diseases in Japan, Journal of gynecologic oncology, 33, e72, 10.3802/jgo.2022.33.e72 Lurain, 2005, Secondary chemotherapy for high-risk gestational trophoblastic neoplasia, Gynecol Oncol, 97, 618, 10.1016/j.ygyno.2005.02.004 Powles, 2007, A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia, Br J Cancer, 96, 732, 10.1038/sj.bjc.6603608 Sato, 2020, The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia, Int J Clin Oncol, 25, 203, 10.1007/s10147-019-01540-9 Bell, 2021, An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab, Gynecologic oncology reports, 37, 10.1016/j.gore.2021.100819 Choi, 2019, vol. 121, 94 Clair, 2020, Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors, Gynecologic oncology reports, 34, 10.1016/j.gore.2020.100625 Ghorani, 2017, Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia, Lancet (London, England), 390, 2343, 10.1016/S0140-6736(17)32894-5 Wong, 2022, Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy, Gynecologic oncology reports, 40, 10.1016/j.gore.2022.100955 Yamamoto, 2016, High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: a case report and literature review, Molecular and clinical oncology, 5, 660, 10.3892/mco.2016.1011 Inaguma, 2016, Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1): analysis in 5536 cases revealed consistent expression in trophoblastic tumors, Am J Surg Pathol, 40, 1133, 10.1097/PAS.0000000000000653 Liu, 2019, Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer, Gynecol Oncol, 155, 51, 10.1016/j.ygyno.2019.08.006 Horn, 2018, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer, N Engl J Med, 379, 2220, 10.1056/NEJMoa1809064 Schmid, 2018, Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, N Engl J Med, 379, 2108, 10.1056/NEJMoa1809615 Eskander, 2023, Pembrolizumab plus chemotherapy in advanced endometrial cancer, N Engl J Med, 388, 2159, 10.1056/NEJMoa2302312 Mirza, 2023, Dostarlimab for primary advanced or recurrent endometrial cancer, N Engl J Med, 388, 2145, 10.1056/NEJMoa2216334 Wang, 2016, Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer, Cell, 165, 1092, 10.1016/j.cell.2016.04.009